- WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy ...
SHANGHAI, Jan. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
* The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities i...
* Identified as a global sustainability leader by S&P Global * Committed to generating long-term...
* Ranked in top 1% of the over 100,000 companies evaluated * Recognized for outstanding performa...
* By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug subst...
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Cont...
* WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibilit...
WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global C...
SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Con...
- In response to global clients' increasing demand for contract manufacturing services, WuXi Biolo...
DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading gl...
* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-cl...
* The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10%...
WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global...
Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million Gross Profit Increased by 39.2% Y-o-Y to R...
* WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell ...
SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Cont...
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Co...
- The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global ma...